Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI

Journal of Nuclear Medicine

Volumn 53, Issue 7, 2012, Pages 1048-1057

  Galldiks, Norbert ^a,b   Langen, Karl Josef ^a,c   Holy, Richard ^c,d   Pinkawa, Michael ^c,d   Stoffels, Gabriele ^a,c   Nolte, Kay W ^c,d   Kaiser, Hans J ^c,d   Filss, Christan P ^a,c   Fink, Gereon R ^a,b   Coenen, Heinz H ^a,c   Eble, Michael J ^c,d   Piroth, Marc D ^c,d  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Section JARA FIT   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

18F fluoroethyl L tyrosine (18F FET); Amino acid PET; Assessment of treatment response; Glioblastoma; Prognosis

Indexed keywords

GADOLINIUM PENTETATE; O (2 FLUOROETHYL)TYROSINE F 18; TEMOZOLOMIDE; TRACER; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY CANCER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR TO BRAIN RATIO; TUMOR VOLUME;

ADULT; AGED; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CONTRAST MEDIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GADOLINIUM; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TYROSINE;

EID: 84863496617     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.098590     Document Type: Article

References (37)

1. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99:467-473. (Pubitemid 37040405)
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
3. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123. (Pubitemid 32052502)
4. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000;217:377-384.
5. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
6. Yang I, Aghi MK. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol. 2009;6:648-657.
7. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445. (Pubitemid 32207394)
8. 18F]fluoroethyl) -L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687.
9. 18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31:1464-1470.
10. 11C- methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging. 2006;33:516-524.
11. 11C-methionine and survival in patients with low-grade gliomas. Cancer. 2001;92: 1541-1549.
12. 18F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging. 2006;33:792-800.
13. 18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005;32:1018-1025.
14. 18F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol. 2011;99:218-224.
15. Thiele F, Ehmer J, Piroth MD, et al. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys Med Biol. 2009;54:5525-5539.
16. 18F- fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011;52:856-864.
17. 18F]fluoroethyl-tyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;80:176-184.
18. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710. (Pubitemid 23133591)
19. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
20. International Commission on Radiation Units and Measurements (ICRU). Prescribing, Recording and Reporting Photon Beam Therapy (Report 50). Bethesda, MD: ICRU; 1993. Available at: http://www.icru.org/index.php?option5com- content&task5view&id572. Accessed May 10, 2012.
21. 11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2010;37:84-92.
22. Vollmar S, Hampl J, Kracht L, Herholz K. Integration of functional data (PET) into brain surgery planning und neuronavigation. Springer Proceedings in Physics. 2007;114:98-103.
23. 18F fluoroethyl-L-tyrosine. Appl Radiat Isot. 2002;57:853-856.
24. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
25. 123I]iodo-alpha-methyl tyrosine: competition with natural L-amino acids. J Nucl Med. 1991;32:1225-1229.
26. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L. Chemotherapy response criteria in malignant glioma. Neurology. 1997;48:1336-1340. (Pubitemid 27240560)
27. Levivier M, Becerra A, De Witte O, Brotchi J, Goldman S. Radiation necrosis or recurrence. J Neurosurg. 1996;84:148-149.
28. Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging. 2003;13:269-271. (Pubitemid 36775950)
29. Galldiks N, Kracht LW, Burghaus L, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging. 2010;9:40-46.
30. Galldiks N, Ullrich R, Schroeter M, Fink GR, Kracht LW. Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. J Neurooncol. 2009;93:425-430.
31. Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol. 2009;95:87-93.
32. Chen W, Geist C, Czernin J, et al. Assess treatment response using FDOPA PET in patients with recurrent malignant gliomas treated with bevacizumab and irinotecan [abstract]. J Nucl Med. 2008;49(suppl 1):78P.
33. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906-920.
34. Bobek-Billewicz B, Stasik-Pres G, Majchrzak H, Zarudzki L. Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusionweighted imaging and MR spectroscopy. Folia Neuropathol. 2010;48:81-92.
35. Tsien C, Galban CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010;28:2293-2299.
36. 11C]methioninepositron emission tomographic and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumors in children. Neurosurgery. 2005;57:128-139.
37. 11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81:1049-1058.